vs
Side-by-side financial comparison of Hologic (HOLX) and StoneX Group Inc. (SNEX). Click either name above to swap in a different company.
StoneX Group Inc. is the larger business by last-quarter revenue ($1.2B vs $1.0B, roughly 1.1× Hologic). Hologic runs the higher net margin — 17.1% vs 11.6%, a 5.5% gap on every dollar of revenue. On growth, StoneX Group Inc. posted the faster year-over-year revenue change (81.0% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $-1.3B). Over the past eight quarters, StoneX Group Inc.'s revenue compounded faster (53.5% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
StoneX Group Inc. is an American financial services company. The company operates in six areas: commercial hedging, global payments, securities, physical commodities, foreign exchange and clearing and execution services (CES).
HOLX vs SNEX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.2B |
| Net Profit | $179.1M | $139.0M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 15.4% |
| Net Margin | 17.1% | 11.6% |
| Revenue YoY | 2.5% | 81.0% |
| Net Profit YoY | -10.9% | 63.3% |
| EPS (diluted) | $0.79 | $2.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $1.0B | $32.7B | ||
| Q2 25 | $1.0B | $851.2M | ||
| Q1 25 | $1.0B | $820.4M | ||
| Q4 24 | $1.0B | $663.1M | ||
| Q3 24 | $988.0M | $31.1B | ||
| Q2 24 | $1.0B | $571.8M | ||
| Q1 24 | $1.0B | $509.2M |
| Q4 25 | $179.1M | $139.0M | ||
| Q3 25 | $187.2M | $85.7M | ||
| Q2 25 | $194.9M | $63.4M | ||
| Q1 25 | $-17.4M | $71.7M | ||
| Q4 24 | $201.0M | $85.1M | ||
| Q3 24 | $178.6M | $76.7M | ||
| Q2 24 | $194.5M | $61.9M | ||
| Q1 24 | $169.9M | $53.1M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | 3.7% | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | 3.0% | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | 15.4% | ||
| Q3 25 | 22.6% | 0.3% | ||
| Q2 25 | 24.9% | -1.3% | ||
| Q1 25 | -0.7% | -1.0% | ||
| Q4 24 | 22.5% | -3.2% | ||
| Q3 24 | 23.3% | -0.0% | ||
| Q2 24 | 24.1% | -4.7% | ||
| Q1 24 | 20.7% | -2.5% |
| Q4 25 | 17.1% | 11.6% | ||
| Q3 25 | 17.8% | 0.3% | ||
| Q2 25 | 19.0% | 7.4% | ||
| Q1 25 | -1.7% | 8.7% | ||
| Q4 24 | 19.7% | 12.8% | ||
| Q3 24 | 18.1% | 0.2% | ||
| Q2 24 | 19.2% | 10.8% | ||
| Q1 24 | 16.7% | 10.4% |
| Q4 25 | $0.79 | $2.50 | ||
| Q3 25 | $0.84 | $0.72 | ||
| Q2 25 | $0.86 | $1.22 | ||
| Q1 25 | $-0.08 | $1.41 | ||
| Q4 24 | $0.87 | $1.69 | ||
| Q3 24 | $0.75 | $2.32 | ||
| Q2 24 | $0.82 | $1.25 | ||
| Q1 24 | $0.72 | $1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $1.6B |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $2.5B |
| Total Assets | $9.2B | $47.8B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $1.6B | ||
| Q3 25 | $2.2B | $1.6B | ||
| Q2 25 | $1.9B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $2.0B | $1.4B | ||
| Q3 24 | $2.3B | $1.3B | ||
| Q2 24 | $2.4B | $1.2B | ||
| Q1 24 | $2.2B | $1.3B |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $2.5B | ||
| Q3 25 | $5.0B | $2.4B | ||
| Q2 25 | $4.8B | $2.0B | ||
| Q1 25 | $4.6B | $1.9B | ||
| Q4 24 | $4.8B | $1.8B | ||
| Q3 24 | $5.1B | $1.7B | ||
| Q2 24 | $5.0B | $1.6B | ||
| Q1 24 | $4.8B | $1.5B |
| Q4 25 | $9.2B | $47.8B | ||
| Q3 25 | $9.0B | $45.3B | ||
| Q2 25 | $8.8B | $34.3B | ||
| Q1 25 | $8.5B | $31.3B | ||
| Q4 24 | $8.7B | $29.6B | ||
| Q3 24 | $9.2B | $27.5B | ||
| Q2 24 | $8.9B | $25.9B | ||
| Q1 24 | $8.7B | $25.7B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $-1.3B |
| Free Cash FlowOCF − Capex | $215.2M | $-1.3B |
| FCF MarginFCF / Revenue | 20.5% | -106.4% |
| Capex IntensityCapex / Revenue | 1.4% | 1.3% |
| Cash ConversionOCF / Net Profit | 1.28× | -9.08× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $3.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $-1.3B | ||
| Q3 25 | $355.1M | $3.5B | ||
| Q2 25 | $343.3M | $1.5B | ||
| Q1 25 | $169.4M | $-154.5M | ||
| Q4 24 | $189.3M | $-477.8M | ||
| Q3 24 | $367.0M | $192.6M | ||
| Q2 24 | $405.8M | $-622.1M | ||
| Q1 24 | $292.4M | $784.0M |
| Q4 25 | $215.2M | $-1.3B | ||
| Q3 25 | $341.4M | $3.5B | ||
| Q2 25 | $330.5M | $1.5B | ||
| Q1 25 | $153.9M | $-169.8M | ||
| Q4 24 | $172.5M | $-491.4M | ||
| Q3 24 | $350.6M | $175.9M | ||
| Q2 24 | $385.3M | $-640.5M | ||
| Q1 24 | $279.6M | $766.6M |
| Q4 25 | 20.5% | -106.4% | ||
| Q3 25 | 32.5% | 10.7% | ||
| Q2 25 | 32.3% | 173.3% | ||
| Q1 25 | 15.3% | -20.7% | ||
| Q4 24 | 16.9% | -74.1% | ||
| Q3 24 | 35.5% | 0.6% | ||
| Q2 24 | 38.1% | -112.0% | ||
| Q1 24 | 27.5% | 150.5% |
| Q4 25 | 1.4% | 1.3% | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.3% | 1.9% | ||
| Q1 25 | 1.5% | 1.9% | ||
| Q4 24 | 1.6% | 2.1% | ||
| Q3 24 | 1.7% | 0.1% | ||
| Q2 24 | 2.0% | 3.2% | ||
| Q1 24 | 1.3% | 3.4% |
| Q4 25 | 1.28× | -9.08× | ||
| Q3 25 | 1.90× | 41.18× | ||
| Q2 25 | 1.76× | 23.52× | ||
| Q1 25 | — | -2.15× | ||
| Q4 24 | 0.94× | -5.61× | ||
| Q3 24 | 2.05× | 2.51× | ||
| Q2 24 | 2.09× | -10.05× | ||
| Q1 24 | 1.72× | 14.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SNEX
Segment breakdown not available.
